Biomedical Techs

• Innovative targeted cancer therapeutics 
• Companion diagnostics in the context of Personalised Medicine
• Novel targeted therapies for the Onclology Market
• Collagen beauty product
• Proprietory technology based on stem cell research derived extracellular vesicles (Evs) that can deliver novel therapeutic microRNA sequences directly to the tumor sites of cancer patients

Evs have the following properties:

• They are designed to target and migrate to tumor sites
• Evs loaded with miRNA sequences (EVmiRs) that block multiple cancer pathways

Financial Opportunity:

• The company aims to attract capital investment of up to €1.5m with exchange of company equity
• 300K in funding has already been raised in a successful seed round
• Further investment to fund preclinical development of its proprietary technologies  and to strengthen its patent portfolio
• Seeking investment through private equity and/or other investment mechs to fund preclinical development of its proprietary technologies and to strengthen its patent portfolio
• Licencing of product and secure of further funding from big pharma or VC partners at the end of the current preclinical phase (in 3 years)

‍

‍

‍